Study guide

3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors

Key Takeaways Explain This Topic AI

First-line osimertinib is the preferred standard of care for advanced NSCLC harboring classical EGFR-sensitizing mutations (Exon 19 del, Exon 21 L858R) based on superior progression-free and overall survival and robust CNS penetrance (FLAURA trial); secondary resistance occurs via on-target C797S or off-target bypass tracks (MET/HER2 amplification, small cell transformation).

Next-generation ALK inhibitors (alectinib, brigatinib, lorlatinib) demonstrate superior intracranial activity and systemic efficacy compared to first-generation crizotinib; third-generation lorlatinib uniquely overcomes the formidable ALK G1202R solvent-front resistance mutation but requires proactive monitoring for hyperlipidemia and central neurocognitive effects.

Combined BRAF and MEK inhibition (e.g., dabrafenib + trametinib, encorafenib + binimetinib) improves progression-free survival while suppressing paradoxical MAPK hyperactivation and secondary cutaneous squamous cell carcinomas in melanoma; in metastatic colorectal cancer, encorafenib requires co-administration with cetuximab/panitumumab to prevent rapid EGFR-mediated feedback reactivation.

KRAS G12C is a druggable oncogenic driver targeted by allele-specific covalent switch-II pocket inhibitors (sotorasib, adagrasib) that lock the oncoprotein in its inactive GDP-bound state; in colorectal cancer, rapid EGFR pathway feedback necessitates combination with anti-EGFR monoclonal antibodies.

Agnostic oncogenic drivers—including NTRK1/2/3 gene fusions (targeted by larotrectinib, entrectinib, repotrectinib) and activating HER2 alterations (targeted by trastuzumab deruxtecan)—elicit profound, durable responses across diverse histologies, requiring vigilance for on-target TRK neurotoxicity (dizziness, weight gain, withdrawal pain) and drug-induced interstitial lung disease (ILD).

Last updated: August 2026

Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors

Therapeutic management of advanced solid tumors relies heavily on identifying actionable oncogenic driver mutations—genomic alterations that encode constitutively active signaling proteins essential for tumor initiation, proliferation, and survival. The Board Certified Oncology Pharmacist (BCOP) must understand the structural biology of tyrosine and serine/threonine kinases, the pharmacology of small-molecule inhibitors, predictable mechanisms of on-target and off-target therapeutic resistance, and evidence-based strategies for managing class-specific adverse drug events.

1. Receptor Tyrosine Kinase Signaling & Pharmacologic Principles

Receptor Tyrosine Kinases (RTKs) are transmembrane glycoproteins consisting of an extracellular ligand-binding domain, a hydrophobic transmembrane alpha-helix, and an intracellular catalytic tyrosine kinase domain with regulatory juxtamembrane and C-terminal tails. +---------------------------------------------------------------------------------------------------+

  • | ONCOGENIC RECEPTOR TYROSINE KINASE (RTK) SIGNALING |
  • | |
  • | [EXTRACELLULAR SPACE] Ligand Binding (EGF, HGF, NRG1) OR Oncogenic Fusion (EML4-ALK) |
  • | | |
  • | ========================= CELL MEMBRANE ======================================================= |
  • | | |
  • | [CYTOPLASMIC DOMAIN] Receptor Dimerization & Trans-Autophosphorylation |
  • | | |
  • | +-------------------+-------------------+ |
  • | | | |
  • | v v |
  • | [RAS - RAF - MEK - ERK] [PI3K - AKT - mTOR] |
  • | * Mitogen-Activated Protein * Cell Survival, Growth, & |
  • | Kinase (MAPK) Pathway Metabolic Reprogramming |
  • | * Transcription Factors: Cyclin D1, * Inactivates Pro-Apoptotic BAD & FOXO; |
  • | c-Myc, FOS, JUN Activates S6K, 4E-BP1 |
  • +---------------------------------------------------------------------------------------------------+
  • Small-Molecule Tyrosine Kinase Inhibitor (TKI) Classes

Type I Inhibitors: Bind to the active, open kinase conformation ("DFG-in") directly in the ATP-binding cleft (e.g., erlotinib, crizotinib, dabrafenib).

Type II Inhibitors: Bind to the inactive kinase conformation ("DFG-out") occupying the ATP site and an adjacent hydrophobic allosteric pocket (e.g., sorafenib, cabozantinib, imatinib).

Type III / IV Allosteric Inhibitors: Bind outside the ATP-binding pocket at distinct allosteric regulatory sites (e.g., trametinib binding MEK1/2; asciminib binding the myristoyl pocket of BCR::ABL1).

Covalent (Irreversible) Inhibitors: Form a permanent covalent bond with a specific nucleophilic cysteine residue within the ATP pocket (e.g., osimertinib targeting Cys797 in EGFR ; sotorasib/adagrasib targeting Cys12 in KRAS G12C; ibrutinib targeting Cys481 in BTK ).

2. EGFR Alterations in Non-Small Cell Lung Cancer (NSCLC)

Activating mutations in the Epidermal Growth Factor Receptor ( EGFR ) gene occur in approximately 15% of Western and up to 50% of East Asian patients with advanced lung adenocarcinoma. +---------------------------------------------------------------------------------------------------+

  • | EGFR MUTATION SPECTRUM & TKI GENERATION PHARMACOLOGY |
  • | |
  • | [CLASSICAL SENSITIZING MUTATIONS (~85%-90%)] |
  • | - Exon 19 In-Frame Deletions (e.g., delE746_A750) |
  • | - Exon 21 Point Mutation (L858R) |
  • | |
  • | [EVOLUTION OF TARGETED THERAPY] |
  • | - 1st Generation (Reversible): Erlotinib, Gefitinib |
  • | - 2nd Generation (Irreversible Pan-HER): Afatinib, Dacomitinib |
  • | - 3rd Generation (Irreversible, T790M-sparing, CNS-active): OSIMERTINIB (Standard Frontline) |
  • | |
  • | [MECHANISMS OF RESISTANCE TO FRONTLINE OSIMERTINIB] |
  • | +---------------------------------------+---------------------------------------+ |
  • | | ON-TARGET RESISTANCE (~15%-20%) | OFF-TARGET BYPASS TRACKS (~50%-60%) | |
  • | | * Tertiary EGFR C797S mutation | * MET Gene Amplification (~15%-25%) | |
  • | | (Prevents covalent drug binding) | * HER2 (ERBB2) Amplification | |
  • | | * EGFR G724S, L718Q, L792X mutations | * PIK3CA / BRAF V600E mutations | |
  • | | | * Histologic Small Cell Transformation| |
  • | +---------------------------------------+---------------------------------------+ |
  • +---------------------------------------------------------------------------------------------------+
  • Clinical Evidence: The FLAURA Trial

In the landmark Phase III FLAURA trial, frontline osimertinib demonstrated significant superiority over first-generation TKIs (gefitinib or erlotinib), extending median progression-free survival (18.9 months vs. 10.2 months; HR 0.46) and median overall survival (38.6 months vs. 31.8 months; HR 0.799), with superior central nervous system (CNS) efficacy and lower rates of severe Grade ≥3 acneiform rash and diarrhea due to wild-type EGFR sparing.

Atypical EGFR Mutations: Exon 20 Insertions

Exon 20 insertion mutations (accounting for ~5%–10% of EGFR-mutant NSCLC) cause steric hindrance that prevents binding of first-, second-, and third-generation TKIs. Approved targeted options include:

Amivantamab: A fully human EGFR-MET bispecific monoclonal antibody that binds extracellular domains, inhibits ligand binding, triggers receptor degradation, and engages immune effector cells (ADCC).

3. ALK, ROS1, and RET Receptor Tyrosine Kinase Rearrangements +---------------------------------------------------------------------------------------------------+

  • | ALK TYROSINE KINASE INHIBITOR EVOLUTION & RESISTANCE |
  • | |
  • | [1st GEN: CRIZOTINIB] ---> High systemic response, POOR CNS penetration (~20% intracranial), |
  • | Rapid relapse in brain parenchyma |
  • | | |
  • | v |
  • | [2nd GEN: ALECTINIB] ---> Superior systemic PFS (34.8 mos), EXCELLENT CNS penetration, |
  • | [BRIGATINIB / CERITINIB] Preferred 1st-line standard of care (ALEX trial) |
  • | | |
  • | v (Acquired G1202R Solvent-Front Mutation) |
  • | [3rd GEN: LORLATINIB] ---> Compact structure, crosses blood-brain barrier effortlessly, |
  • | Potently inhibits all known ALK resistance mutations (G1202R); |
  • | First-line (CROWN trial) or salvage option |
  • +---------------------------------------------------------------------------------------------------+
  • Generational Comparison of ALK Tyrosine Kinase Inhibitors

Agent Generation Mechanism & CNS Activity Key Clinical Distinctions & Unique Toxicities

Crizotinib 1st Gen Reversible ATP competitive; P-glycoprotein substrate (poor CNS penetration) Historical comparator; visual disturbances (trails of light), bradycardia, QTc prolongation.

Alectinib 2nd Gen High-affinity ATP competitive; NOT a P-gp substrate (high CNS penetration) Preferred frontline standard; myalgia, asymptomatic CPK elevation, photosensitivity, hyperbilirubinemia.

Brigatinib 2nd Gen Broad-spectrum ALK/EGFR/ROS1; high CNS penetration Early-onset pulmonary syndrome (dyspnea, cough within 3–7 days; requires 90 mg to 180 mg lead-in dosing), hypertension.

Lorlatinib 3rd Gen Macrocyclic ATP competitive; overcomes all secondary ALK kinase mutations including G1202R Hypercholesterolemia and hypertriglyceridemia (>80% of patients; requires prompt statin/fibrate therapy), CNS cognitive/mood effects (hallucinations, memory impairment), peripheral neuropathy.

ROS1 and RET Rearrangements

ROS1 Rearrangements (1%–2% NSCLC):

First-line options: Crizotinib , Entrectinib (preferred for baseline CNS metastases).

Acquired resistance: The solvent-front mutation ROS1 G2032R sterically blocks crizotinib/entrectinib; treated with next-generation macrocyclic inhibitor Repotrectinib .

RET Fusions & Activating Point Mutations:

Indications: RET fusions in NSCLC and papillary thyroid carcinoma; activating RET point mutations (e.g., M918T, C634R) in sporadic or familial (MEN2) Medullary Thyroid Carcinoma (MTC).

Targeted Inhibitors: Selpercatinib and Pralsetinib (selective RET inhibitors that spare VEGFR2, significantly reducing off-target anti-angiogenic toxicities).

Monitoring: Hypertension, QTc interval prolongation, hepatotoxicity, and hemorrhagic events.

4. The MAPK Cascade: BRAF V600E/K and MEK/EGFR Co-Targeting +---------------------------------------------------------------------------------------------------+

  • | BRAF INHIBITION: PARADOXICAL ACTIVATION VS. DUAL PATHWAY BLOCKADE |
  • | |
  • | [SCENARIO 1: BRAF MONOTHERAPY IN BRAF WILD-TYPE / RAS-MUTANT CELLS] |
  • | - BRAF inhibitor binds one monomer of wild-type RAF dimer |
  • | - Triggers conformational change -> PARADOXICAL TRANSACTIVATION of adjacent RAF monomer |
  • | - Hyperactivates downstream MEK -> ERK phosphorylation -> ACCELERATES SECONDARY SKIN TUMORS! |
  • | |
  • | [SCENARIO 2: COMBINED BRAF + MEK INHIBITION (Dabrafenib + Trametinib / Encorafenib + Bini)] |
  • | - BRAF inhibitor shuts down V600E monomer signaling |
  • | - MEK inhibitor blocks any paradoxical downstream ERK activation |
  • | - Result: Markedly higher response rate, longer PFS, AND REDUCED cutaneous squamous neoplasia! |
  • +---------------------------------------------------------------------------------------------------+

Disease-Specific BRAF Treatment Paradigms +---------------------------------------------------------------------------------------------------+

  • | WHY BRAF INHIBITOR MONOTHERAPY FAILS IN COLORECTAL CANCER |
  • | |
  • | [MELANOMA] (Low baseline EGFR expression): |
  • | BRAF V600E Blockade ---> Sustained MAPK Shutdown ---> Robust Tumor Regression |
  • | |
  • | [COLORECTAL CANCER] (High baseline EGFR expression): |
  • | BRAF V600E Blockade ---> Loss of ERK-mediated Negative Feedback ---> Rapid EGFR Receptor |
  • | Hyperactivation ---> Reactivates CRAF/RAS ---> PROLIFERATION! |
  • | |
  • | [THE SOLUTION: BEACON CRC TRIAL] |
  • | Dual Blockade: ENCORAFENIB (BRAF Inhibitor) + CETUXIMAB (Anti-EGFR mAb) |
  • | - Shuts down both the driver oncogene and the adaptive upstream feedback loop! |
  • +---------------------------------------------------------------------------------------------------+

Regimen Approved Disease Setting Critical Dosing & Pharmacokinetics Key Toxicities & Clinical Management

Dabrafenib + Trametinib Melanoma (unresectable/metastatic or adjuvant), BRAF V600E NSCLC, Anaplastic Thyroid Cancer, Agnostic Solid Tumors Dabrafenib 150 mg PO BID (take on empty stomach, 1h before or 2h after meals) + Trametinib 2 mg PO daily (refrigerate capsules) Pyrexia (fever >38.5°C in >50%): Manage by withholding dabrafenib at onset of fever, administering antipyretics, and considering low-dose oral corticosteroids for recurrent refractory fevers; LVEF reduction, ocular toxicity (uveitis, RPED).

Encorafenib + Cetuximab Metastatic Colorectal Cancer ( BRAF V600E) after prior systemic therapy (BEACON CRC) Encorafenib 300 mg PO daily + Cetuximab 400 mg/m2 IV load then 250 mg/m2 weekly (or 500 mg/m2 q2w) Acneiform rash, fatigue, diarrhea, hypomagnesemia (from cetuximab-induced renal magnesium wasting).

5. KRAS G12C Covalent Inhibitors: Sotorasib & Adagrasib

For four decades, KRAS was deemed "undruggable" due to its picomolar affinity for GTP/GDP and lack of deep hydrophobic allosteric binding pockets. The discovery of a druggable pocket beneath the effector-binding switch-II region ( SW-II pocket ) enabled the synthesis of mutant-specific covalent inhibitors that trap the mutant KRAS G12C protein in its inactive GDP-bound state. +---------------------------------------------------------------------------------------------------+

  • | KRAS G12C ALLELE-SPECIFIC SWITCH-II POCKET INHIBITION |
  • | |
  • | +----------------------------------------------------+ |
  • | | Active State (GTP-Bound) <=====> Inactive (GDP) | |
  • | +----------------------------------------|-----------+ |
  • | | |
  • | v |
  • | [SOTORASIB / ADAGRASIB] |
  • | - Enters open Switch-II Pocket |
  • | - Forms irreversible covalent bond with Cysteine 12 |
  • | - Locks KRAS in GDP-bound OFF state |
  • +---------------------------------------------------------------------------------------------------+
  • Clinical Pharmacologic Comparison

Sotorasib: Approved for locally advanced or metastatic KRAS G12C-mutated NSCLC following at least one prior systemic therapy. Primary toxicities include diarrhea, musculoskeletal pain, and hepatotoxicity (ALT/AST elevations).

Adagrasib: Formulated with optimized pharmacokinetic properties, including a long half-life (~23 hours), dose-dependent CNS penetration, and tissue accumulation. Approved for KRAS G12C NSCLC and metastatic colorectal cancer (in combination with cetuximab). Carries monitoring requirements for QTc interval prolongation and GI toxicities.

  • 6. Agnostic Drivers: NTRK Gene Fusions & HER2 Exon 20 Insertions
  • Neurotrophin Receptor Kinase (NTRK) Fusions

NTRK1 , NTRK2 , and NTRK3 encode TRKA, TRKB, and TRKC neurotrophin receptors essential for central and peripheral nervous system development. Chimeric fusions (e.g., ETV6-NTRK3 ) cause constitutive ligand-independent downstream oncogenic signaling.

Drug Generation Key Activity & Indications Characteristic Toxicities

Larotrectinib 1st Gen Pan-TRK (TRKA/B/C) inhibitor; FDA tissue-agnostic approval for all solid tumors with NTRK fusion On-target neurotoxicity: Dizziness, ataxia, cognitive changes, weight gain (via TRKB appetite regulation), and transient withdrawal pain upon drug interruption.

Entrectinib 1st Gen Dual Pan-TRK and ROS1 inhibitor; crosses blood-brain barrier Dysgeusia, paresthesias, weight gain, congestive heart failure, hyperuricemia.

Repotrectinib Next Gen Macrocyclic inhibitor targeting TRK and ROS1; overcomes solvent-front resistance mutations ( TRKA G595R , TRKC G623R ) Dizziness (very high incidence), paresthesias, ataxia.

HER2 (ERBB2) Activating Alterations in NSCLC and Breast Oncology

While HER2 gene amplification is classically targeted by naked monoclonal antibodies (trastuzumab, pertuzumab) and small-molecule TKIs (tucatinib), activating ERBB2 Exon 20 insertion mutations in lung adenocarcinoma are exquisitely targeted by antibody-drug conjugates (ADCs):

Trastuzumab Deruxtecan (T-DXd): Composed of an anti-HER2 IgG1 antibody attached to a topoisomerase I inhibitor payload (deruxtecan, exatecan derivative) via a cleavable tetrapeptide linker with a high drug-to-antibody ratio (DAR 8:1). FDA approved for unresectable/metastatic HER2 -mutant NSCLC.

Black Box Warnings: Interstitial Lung Disease (ILD) / pneumonitis (requires immediate discontinuation and systemic corticosteroid initiation at Grade ≥2) and embryo-fetal toxicity.